Best in Biotech 15 Mar 2017 What are the Best Countries to Recruit Biotech Talents in 2017? Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […] March 15, 2017 - 10 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Infographics 21 Feb 2017 Infographic: The Biggest Biotech Company in Each European Country We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest employers in Europe, where companies of all sizes strive to bring the most innovative technology to the market. To illustrate the dynamic biotech ecosystem in […] February 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 Actelion’s key Drug linked to Deaths, prompting EMA Investigation Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […] February 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2017 Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […] January 26, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2017 A Placebo beats the Largest European Biotech in Phase III Actelion’s lead drug Opsumit has missed its primary endpoint in Phase III. What are the consequences for the biggest independent biotech in Europe? Actelion is a leader in treatments for pulmonary arterial hypertension (PAH). However, results from a Phase III trial evaluating Opsumit (macitentan) in patients with PAH due to Eisenmenger Syndrome have revealed that the drug […] January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jan 2017 UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […] January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 5 Jan 2017 What to Expect from European Biotech Finance in 2017 The new year comes with uncertainty over the future of the biotech industry, whose finance suffered during 2016. What are the expert predictions for 2017? Last year was the worst for biotech finance in a decade. Despite the struggle, some companies managed to make outstanding deals, fundraising and exits in 2016 and experts seem convinced that the […] January 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […] December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 Here comes the First-ever Combination Therapy for Multiple Sclerosis Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […] October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email